<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">20399261</PMID>
        <DateCompleted>
            <Year>2010</Year>
            <Month>09</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-3476</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>393</Volume>
                    <Issue>1-2</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Jun</Month>
                        <Day>30</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of pharmaceutics</Title>
                <ISOAbbreviation>Int J Pharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A pharma-robust design method to investigate the effect of PEG and PEO on matrix tablets.</ArticleTitle>
            <Pagination>
                <MedlinePgn>79-87</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijpharm.2010.04.009</ELocationID>
            <Abstract>
                <AbstractText>Even though polyethyleneoxide (PEO)-polyethyleneglycol (PEG) blends have been used widely for sustained release matrix tablets, evaluations of the effects of PEG or PEO on the matrix properties have been limited. In order to evaluate gelling behavior and drug release profiles of PEG, various contents of the polymers were investigated through a robust experimental design method. When exposed to an aqueous environment, the PEO-PEG matrix hydrated slowly and swelled, causing a thick gel layer to form on the surface, the thickness of which increased significantly depending on the PEG contents. Since polyacrylate plates were used for the study, the matrix was not completely hydrated and gelled even after 5h. However, the results could be applied to the time-oriented responses RD (robust design) models to obtain optimal settings and responses for the observed times. The optimal settings of PEO and PEG were 94.26 and 140.04 mg, respectively (PEG rate of 148.57%). Moreover, as the amount of PEG increased, the release rate also increased. When the formulation contained more than 150% of PEG, most of the drug loaded in the tablet was released in about 12 h. When the amount of PEG was less than 100%, the drug release rate was sustained significantly. Based on the RD optimization model for drug release, the optimal settings were PEG and PEO of 124.3 and 110 mg, respectively (PEG rate of 88.50%). Therefore, PEG rate of about 90-150% is suggested for matrix tablet formulations, and the exact ratio could be formulated according to the resulting tablet's properties.</AbstractText>
                <CopyrightInformation>2010 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Jun Sang</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>GL PharmTech Corp., Seongnam, Gyeonggi, 462-807, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shim</LastName>
                    <ForeName>Ji Yeon</ForeName>
                    <Initials>JY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Khoa Viet Truong</ForeName>
                    <Initials>KV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Jung Soo</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shin</LastName>
                    <ForeName>Sangmun</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Young Wook</ForeName>
                    <Initials>YW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jaehwi</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoon</LastName>
                    <ForeName>Jeong-Hyun</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeong</LastName>
                    <ForeName>Seong Hoon</ForeName>
                    <Initials>SH</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>04</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Int J Pharm</MedlineTA>
            <NlmUniqueID>7804127</NlmUniqueID>
            <ISSNLinking>0378-5173</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005782">Gels</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013607">Tablets</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>059QF0KO0R</RegistryNumber>
                <NameOfSubstance UI="D014867">Water</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
                <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8L5014XET7</RegistryNumber>
                <NameOfSubstance UI="C041226">Terazosin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>XM03YJ541D</RegistryNumber>
                <NameOfSubstance UI="D011224">Prazosin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004058" MajorTopicYN="N">Diffusion</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005782" MajorTopicYN="N">Gels</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008956" MajorTopicYN="Y">Models, Chemical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015233" MajorTopicYN="Y">Models, Statistical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011224" MajorTopicYN="N">Prazosin</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013678" MajorTopicYN="N">Technology, Pharmaceutical</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014867" MajorTopicYN="N">Water</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2010</Year>
                <Month>04</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2010</Year>
                <Month>04</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>4</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>4</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>9</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20399261</ArticleId>
            <ArticleId IdType="pii">S0378-5173(10)00281-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2010.04.009</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
